<DOC>
	<DOCNO>NCT02975570</DOCNO>
	<brief_summary>The propose study randomize adult ( 18 year age old ) pulmonary MDR-TB sputum contain M. tuberculosis isoniazid rifampin resistant MTBDRplus fluoroquinolone susceptible MTBDRsl HIV seropositive ( without antiretroviral therapy ) negative ( unknown ) Karnofsky score &gt; 60 site Moldova , Peru , Philippines . Patients MDR-TB randomized oral regimen delamanid ( DLM ) , linezolid ( LZD ) , levofloxacin ( LFX ) pyrazinamide ( PZA ) 24 , 32 , 40 , 48 56 week World Health Organization ( WHO ) standard care MDR-TB regimen ( 9-month `` modify Bangladesh '' regimen WHO standard MDR-TB regimen ) . Primary Objective 1 . Determine short duration delamanid-containing oral regimen non-inferior blend WHO standard regimen . Secondary Objective 1 . Define safety tolerability oral delamanid , linezolid , levofloxacin pyrazinamide regimen . 2 . Determine baseline PZA susceptibility associate short time non-inferior treatment duration . 3 . Identify relationship delamanid linezolid serum drug level time sputum culture conversion among patient delamanid-containing oral regimen . 4 . Identify relationship delamanid linezolid serum drug level occurrence adverse event among patient delamanid-containing oral regimen .</brief_summary>
	<brief_title>Efficacy Tolerability Delamanid , Linezolid , Pyrazinamide Levofloxacin</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>1 . Men woman age ≥18 year 2 . Subject pulmonary TB 3 . Sputum Smear , culture Xpert MTB/RIF assay positive , Hain MTBDRplus show Rifampin ( RIF ) resistance Isoniazid ( INH ) resistance Hain MTBDRsl show Fluoroquinolone susceptibility . 4 . Patients within two week ( ≤14 day ) start secondline antiTB drug 5 . HIV seropositive seronegative unknown HIV serostatus . If last document negative HIV test 3 month prior randomization current serostatus must assess . 6 . Karnofsky score &gt; 60 ( see Appendix B ) screen randomization 7 . Willingness patient attend schedule followup visit undergo study assessment . 8 . Women childbearing potential must agree practice adequate birth control abstain heterosexual intercourse study regimen . 9 . Laboratory parameter ( perform within 14 day prior randomization ) : Estimated Serum creatinine &lt; 2.0 Hemoglobin concentration ≥ 7.0 g/dL Platelet count ≥ 80,000/mm3 Absolute neutrophil count ( ANC ) &gt; 2000/ mm3 Negative pregnancy test ( woman childbearing potential ) randomization/baseline CD4 count HIV infect ( within 6 month ) Serum ALT total bilirubin &lt; 3 time upper limit normal Serum albumin &gt; 2.8 g/dL 10 . Able provide inform consent 1 . Known quinoloneresistance 2 . History serotonin syndrome 3 . History symptomatic arrhythmia , take antiarrhythmic agent 4 . Previous treatment delamanid linezolid 5 . Known allergy intolerability quinolone pyrazinamide 6 . Patients pregnant unwilling use proper contraceptive childbearing age 7 . Medical history galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption 8 . The need ongoing use prohibit drug study drug ( see section 5.6 ) 9 . History optic neuropathy peripheral neuropathy 10 . History hypersensitivity reaction study drug 11 . Patient eligible delamanid bedaquiline national program criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>